Key Highlights

  • Adaptive Biotechnologies shares are trading up 1.47% today to $24.91, holding steady near their 52-week high.
  • The move builds on last week's second-quarter results, which featured revenue of $71.6 million, up 22% year-over-year, beating estimates.
  • Core clonoSEQ MRD franchise revenue grew 43% year-over-year on 43% growth in test volume, with over 36,100 tests delivered.
  • Adjusted EPS loss of $0.25 missed consensus, though the company raised its full-year MRD revenue guidance to $268 million to $278 million.
  • Sentiment remains constructive following price target increases from Guggenheim and BTIG to $25, even as some analysts flag the stock's stretched valuation.

What's Driving Shares Today

Adaptive Biotechnologies (NASDAQ:ADPT), founded in 2009 and headquartered in Seattle, Washington, is a commercial-stage biotechnology company harnessing the biology of the adaptive immune system to transform disease diagnosis and treatment. The company operates through two core segments: Minimal Residual Disease Diagnostics, anchored by its FDA-cleared clonoSEQ test for monitoring blood cancers such as multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, and Immune Medicine, which leverages its proprietary immunoSEQ sequencing platform.

Shares are holding steady near their 52-week high today as investors continue to digest the strong second-quarter results reported this week, which featured revenue of $71.6 million, up 22% year-over-year, beating estimates driven by 43% volume growth in the core clonoSEQ MRD franchise, even as adjusted EPS loss of $0.25 missed consensus.

MRD Business Driving Growth and Guidance Raise

The MRD business, which contributed 92% of revenue in the quarter, grew 33% versus the second quarter of 2025, with MRD sequencing gross margin expanding to 71% to 72%, up nine percentage points year-over-year. CEO Chad Robins said the company delivered an exceptional second quarter, driven by expanding growth and profitability in MRD across both its clinical and biopharma businesses. Adaptive raised full-year MRD revenue guidance to $268 million to $278 million, up from a prior $260 million to $270 million range, with clinical volume growth now expected at 38% to 40%, up from a prior 35% forecast.

The company also strengthened its balance sheet via a $340 million zero coupon convertible note offering paired with a cap call transaction and share repurchase, ending the quarter with approximately $357 million in cash. Key growth drivers included blood-based testing reaching 51% of total Clonoseq volume, up 68% year-over-year, and MRD Pharma backlog of approximately $245 million, up 12% year-over-year.

Strategic Separation Advancing

Management continues to advance a strategic separation of its MRD and Immune Medicine businesses, with Morgan Stanley retained as an advisor. The company also decided to wind down its research-use-only pharma services business and expects to identify a preferred separation path by year-end. Some analysts flag the stock's roughly 11.9x price-to-sales multiple as stretched after shares surged over 40% year-to-date and 118% over the past year.

Conclusion

Adaptive Biotechnologies' steady performance near 52-week highs reflects continued investor confidence in the company's MRD diagnostics franchise, even as the planned business separation and premium valuation introduce some near-term uncertainty. With clonoSEQ test volume accelerating and full-year guidance raised for the second consecutive quarter, today's stability suggests the market has largely absorbed last week's results and is now looking ahead to the next steps in the company's strategic separation process.

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.